Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

por Carrasco, J, Gizzi, M, Pairet, G, Lannoy, V, Lefesvre, P, Gigot, J-F, Hubert, C, Jouret-Mourin, A, Humblet, Y, Canon, J-L, Sempoux, C, Chapaux, X, Danse, E, Tinton, N, Navez, B, Van den Eynde, M
Publicado 2015

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

por van Marcke, C., Honoré, N., van der Elst, A., Beyaert, S., Derouane, F., Dumont, C., Aboubakar Nana, F., Baurain, J. F., Borbath, I., Collard, P., Cornélis, F., De Cuyper, A., Duhoux, F. P., Filleul, B., Galot, R., Gizzi, M., Mazzeo, F., Pieters, T., Seront, E., Sinapi, I., Van den Eynde, M., Whenham, N., Yombi, J. C., Scohy, A., van Maanen, A., Machiels, J. P.
Publicado 2021